Immune thrombocytopenia (ITP)
Clinical trials for Immune thrombocytopenia (ITP) explained in plain language.
Never miss a new study
Get alerted when new Immune thrombocytopenia (ITP) trials appear
Sign up with your email to follow new studies for Immune thrombocytopenia (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Donor CAR-T cells aim to reset a misguided immune system
Cure Not yet recruitingResearchers are testing a new cell therapy called CHT105 in up to 24 adults with relapsed or refractory autoimmune diseases, including immune thrombocytopenia (ITP). CHT105 uses donor-derived CAR-T cells engineered to target two markers, CD19 and CD70, on immune cells. The goal i…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Sponsor: Nanjing Miracle Biotechnology Co., Ltd. • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
Disease control Not yet recruitingThis early-stage trial is testing an experimental therapy called RXIM002 in adults with relapsed or refractory autoimmune cytopenias, including immune thrombocytopenia (ITP). The therapy uses a special RNA molecule to instruct the body to produce CAR T cells that target and poten…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase 1 • Sponsor: RiboX Therapeutics Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a bispecific antibody tame two autoimmune blood disorders?
Disease control Not yet recruitingThis trial is testing an investigational drug called velinotamig in adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has relapsed or not responded to standard treatments. Velinotamig is an engineered bispecific antibody designed to target…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase 1/2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo aims to tame stubborn blood disorders
Disease control Not yet recruitingThis early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop …
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase 1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered immune cells take on stubborn blood disorder
Disease control Not yet recruitingThis early-phase trial will test a new type of CAR T-cell therapy, called QT-019C, in 27 adults with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The therapy uses donor-derived immune cells engineered to targe…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill raises hopes for low platelet disorder
Disease control Not yet recruitingThis early-stage trial tests golidocitinib, an oral drug, in adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. The study has two parts: first, finding a safe dose, then comparing the drug against a placebo in a blinded fashion. T…
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Phase 1/2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
500 ITP patients under the microscope: what real clinics reveal about treatment
Knowledge-focused Not yet recruitingThis study will review medical records of 500 people with newly diagnosed or persistent immune thrombocytopenia (ITP) across multiple hospitals in China. Researchers will look at what treatments patients actually received and how well they worked, without influencing their care. …
Matched conditions: IMMUNE THROMBOCYTOPENIA (ITP)
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC